Pulmonary hypertension refers to the clinical and pathophysiological syndrome that changes the structure or function of pulmonary vessels caused by a variety of heterogenous diseases (etiologies) and different pathogenesis, causing the increase of pulmonary vascular resistance and pulmonary artery pressure, and then develops into right heart failure or even death. It is a common and frequently occurring disease with high morbidity and mortality. Currently, targeted drugs can improve quality of life in PAH patients, but long-term outcomes and prognosis remain poor.Traditional Chinese medicine can effectively improve clinical symptoms and health status, but the outcome report of clinical trials shows that there is heterogeneity, and the selective report in clinical trials also has the risk of bias, which makes it unable to be included in the systematic review. Therefore, it is very necessary and urgent to establish a Core outcome set (COS) on TCM for pulmonary hypertension.
AimTo develop a Core Outcome Set for TCM for pulmonary hypertension.
ContributorsMengmeng Qiu
Disease Category: Heart & circulation
Disease Name: Pulmonary hypertension
Age Range: 0 - 100
Sex: Either
Nature of Intervention: Traditional Chinese Medicine
- Clinical experts
- Conference participants
- Consumers (caregivers)
- Consumers (patients)
- Methodologists
- Patient/ support group representatives
- Researchers
- COS for clinical trials or clinical research
- COS for practice
- Consensus meeting
- Delphi process
- Interview
- Literature review
- Systematic review
(1) Systematic literature review;
(2) Qualitative semi-structured interviews;
(3) Two rounds Delphi survey;
(4) Consensus conference